R97.21Billable

Rising PSA following treatment for malignant neoplasm of prostate

Short description: Rising PSA fol treatment for malignant neoplasm of prostate

Chapter
18. Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified
Category
R97
Effective date
October 1, 2026

Related codes in category R97

R97Abnormal tumor markersR97.0Elevated carcinoembryonic antigen [CEA]YesR97.1Elevated cancer antigen 125 [CA 125]YesR97.2Elevated prostate specific antigen [PSA]R97.20Elevated prostate specific antigen [PSA]YesR97.8Other abnormal tumor markersYes

Frequently asked questions

What is ICD-10 code R97.21?

R97.21 is an ICD-10-CM diagnosis code for Rising PSA following treatment for malignant neoplasm of prostate.

Is R97.21 a billable code?

Yes. R97.21 is billable and specific enough to be used on a claim.

What ICD-10-CM chapter is R97.21 in?

R97.21 falls under Chapter 18: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified.

When did R97.21 become effective?

R97.21 has been effective since October 1, 2026, per the CMS/CDC ICD-10-CM annual release.

What other codes are related to R97.21?

R97.21 belongs to category R97, which includes 6 other codes — see the related codes list on this page.

ICD-10-CM data maintained by CDC/CMS (public domain). Always verify codes with authoritative sources before making coding or billing decisions.